Fall in Boston

Far too many cancer drugs end up being pursued for the wrong reasons in the wrong setting, which is a dreadful waste of time, money, and resources. The focus lately on speed has not helped matters either and yet companies often forget the first-in-class to market agent doesn’t guarantee best-in-class performance.

With the upcoming ENA and SITC meetings there will likely be a veritable smorgasbord of different immunotherapies being presented, not to mention a variety of new combinations or regimens to consider – how should we proceed in terms of thinking about the data coming out and which framework should we use to assess them?

In this post we offer some tips and perspective on how we should perhaps be thinking about outcome measures, and in particular the use of biomarkers, when it comes to interpreting the results from early phase clinical trials that will be presented at these meetings.

To continue reading our latest discussion on oncology new product development plus expert commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by